Nervous System and Brain Disorders

Prof. Illana

Gozes

Therapeutics for autism and beyond

Prof. Gozes discovered and studies Activitydependent neuroprotective protein (ADNP), recognized as a leading gene accounting for 0.17% of autism spectrum disorder (ASD) cases globally. The Gozes laboratory focuses on genome editing, to test and develop therapeutics such as the ADNP enhancing fragment NAP (CP201) and pipeline products, for effects on autism and other ASDrelated predicaments. Prof. Gozes further discovered convergence among autism, schizophrenia, stressrelated ailments and https://www.adnpkids.com/illana-gozes.html

Prof. Gozes, PhD, (Emerita) is Head of the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology, and at the Department of Human Molecular Genetics and Biochemistry, the Adams Super Center for Brain Studies and Sagol School of Neuroscience. She is Chief Scientific Officer at Coronis Neurosciences,with her BSc, from Tel Aviv University, Direct PhD, from Weizmann Institute of Science, Israel, postdoc at MIT and Salk Institute, and was a Senior Scientist/Associate Professor at the Weizmann Institute and Fogarty-Scholar-in-Residence at the NIH, USA. Prof. Gozes has won many awards of excellence, including Tel Aviv University’s Vice President Award, Olson Prize, Julodan Prize, Teva Prize, Neufeld Award, Hanse-Wissenschaftskolleg (HWK) Fellowship, Humboldt Award, the Landau Prize for Life Achievements and the RARE Champion of Hope Award. She currently serves as Secretary of the European Society for Neurochemistry, is a member of the Israeli Ministry of Education, Council of Higher Education and is the Editor-in-Chief of the Journal of Molecular Neuroscience.

Alzheimer’s disease with ADNP playing a role in all of these diseases. As such, the Gozes laboratory strives to pave the way to novel diagnostics and treatments toward healthy development, maturation and aging of the brain.